While most business leaders want to avoid a no-deal departure, continued uncertainty is not much better. With the cliff edge looming, and the prospect of another one in three months if the EU grants Parliament’s request for a further delay, collateral damage is mounting.
Given that Johnson & Johnson’s lawyers made public statements this month that the company’s talc-based products were free of asbestos, the recall couldn’t come at a worse time.
Airbus SE said it has taken steps to shield itself from cyberattacks targeting the European aerospace and defense company through subcontractors’ computer systems.
The three major U.S. pharmacy chains are removing versions of the heartburn drug Zantac from store shelves as health regulators investigate a probable carcinogen detected in the popular stomach drugs.
A California congresswoman plans to hold a hearing in about a month to explore the national-security risks posed by China’s dominance of the U.S. pharmaceutical supply chain, escalating concerns raised by the Pentagon.
Multiple reports are emerging from Xinjiang about human rights abuses against the indigenous Uyghur population, including mass detentions and the use of forced and child labor in local factories.
Manufacturers, retailers and distributors looking to make better use of working capital have a number of creative options at their disposal. But many prefer simply to slow-pay their suppliers.